(Q38097494)

28 August 2017

title

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis (English)

1 reference

28 August 2017

1 reference

1 reference

Bernard Bannwarth

1

1 reference

28 August 2017

Marie Kostine

series ordinal

2

1 reference

28 August 2017

Nicolas Poursac

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

9 April 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

753-761

1 reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Clinical safety of tocilizumab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Management of rheumatoid arthritis: the 2012 perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Regulation of drug metabolism and disposition during inflammation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789500

10.1517/17425255.2013.789500

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference